dc.contributor.author |
Namuganga, Anna Ritah |
|
dc.contributor.author |
Chegou, Novel N. |
|
dc.contributor.author |
Mubiri, Paul |
|
dc.contributor.author |
Walzl, Gerhard |
|
dc.contributor.author |
Mayanja-Kizza, Harriet |
|
dc.date.accessioned |
2021-01-01T21:58:02Z |
|
dc.date.available |
2021-01-01T21:58:02Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
1471-2334 |
|
dc.identifier.uri |
http://combine.alvar.ug/handle/1/48131 |
|
dc.description.abstract |
Background: In the search for fast, simple and better ways for diagnosis of tuberculosis (TB), there is need to discover and evaluate new biomarkers that are found in samples other than sputum to determine their effectiveness. This study examined the utility of saliva vis-a-vis serum by evaluating levels of biomarkers found in saliva and serum from TB suspects. Methods: Study enrolled tuberculosis suspects. Sputum MGIT was used as the gold standard for active TB. Quantiferon gold-In tube assay was done to identify exposure to Mycobacterium tuberculosis (M.tb). Multiplex assay was run for 10 markers using a 10 plex customized kit from Bio-Rad Laboratories. Results: There was a significant difference between saliva and serum marker levels. Saliva had significantly higher levels of GM-CSF and VEGF. Serum had higher levels of MIP-1a, b, TNF-a, G-CSF and IFN-g. Serum levels of IL-6, VEGF and TNF-a were significantly different between participants with active TB disease and those with other respiratory diseases. Conclusion: Salivary TB biomarkers are worth the search to evaluate their ability to differentiate between TB disease states for generation of a non invasive point of care test for TB diagnosis. |
|
dc.description.sponsorship |
European and Developing Clinical Trials Partnership (EDCTP) through African European Tuberculosis Consortium (AE-TBC) [IP_2009_32040] |
|
dc.language |
English |
|
dc.publisher |
BMC |
|
dc.relation.ispartof |
BMC Infectious Diseases |
|
dc.subject |
Biomarkers |
|
dc.subject |
Quantiferon |
|
dc.subject |
Saliva |
|
dc.title |
Suitability of saliva for Tuberculosis diagnosis: comparing with serum |
|
dc.type |
Article |
|
dc.identifier.isi |
000408721200001 |
|
dc.identifier.doi |
10.1186/s12879-017-2687-z |
|
dc.identifier.pmid |
288597 |
|
dc.publisher.city |
LONDON |
|
dc.publisher.address |
CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND |
|
dc.identifier.volume |
17 |
|
dc.subject.wc |
Infectious Diseases |
|
dc.subject.sc |
Infectious Diseases |
|
dc.description.oa |
DOAJ Gold |
|
dc.description.oa |
Green Published |
|
dc.description.pages |
11 |
|
dc.subject.kwp |
Biomarkers |
|
dc.subject.kwp |
Cytokines |
|
dc.subject.kwp |
Assays |
|
dc.subject.kwp |
Tb |
|
dc.identifier.articleno |
600 |
|
dc.description.affiliation |
Joint Clin Res Ctr, Kampala, Uganda |
|
dc.description.affiliation |
Stellenbosch Univ, Div Mol Biol & Human Genet, Dept Biomed Sci, DST NRF Ctr Excellence Biomed TB Res,Fac Med & Hl, Cape Town, South Africa |
|
dc.description.affiliation |
Stellenbosch Univ, Fac Med & Hlth Sci, SAMRC Ctr TB Res, Cape Town, South Africa |
|
dc.description.affiliation |
Uganda Case Western Res Collaborat, Mulago Kampala, Uganda |
|
dc.description.affiliation |
Makerere Univ, Coll Hlth Sci, Kampala, Uganda |
|
dc.description.email |
annamuganga@gmail.com |
|
dc.description.corr |
Namuganga, AR (corresponding author), Joint Clin Res Ctr, Kampala, Uganda.; Namuganga, AR (corresponding author), Uganda Case Western Res Collaborat, Mulago Kampala, Uganda. |
|
dc.description.orcid |
Mayanja-Kizza, Harriet/0000-0002-9297-6208 |
|
dc.description.orcid |
Chegou, Novel N/0000-0002-8690-1699 |
|